Bringing clinical trials to patients with the decentralized model

Since, COVID-19, which has had a huge impact on global clinical trials, sponsors, CROs, sites, and patients have pivoted to adapt to a more home- or community-based approach. Learn why bringing a trial to a patient’s home – with the help of home healthcare support, telemedicine and sensors, direct-to-patient drug shipments, and more –helps to minimize the barriers to recruitment and retention.


Open PDF

Return to Insights Center

Related Insights

Blog

Adapting the validation process for PROs for rare diseases and other diseases with large unmet need and/or rapid progression

Apr 23, 2024

Report

New Medicines, Novel Insights: Achieving patient-guided drug development

Oct 30, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Video

The FDAs Race and Ethnic Diversity Plan Guidance: How prepared is your organization?

Feb 1, 2023

Article

Australia: Infrastructure and Innovations for Clinical Trials

Aug 28, 2023

Blog

A patient-centric approach to managing clinical trial complexity

Jul 13, 2021

Blog

Including patients in DCT design

Sep 13, 2022

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

Decentralized Trials: Considerations for Building a New Patient-Centric Model

May 13, 2021

Article

Decentralized clinical trials - A more patient-centric approach

May 10, 2021

Podcast

Decentrally Speaking | Episode 3: Integrating the Patient Voice into Decentralized Trials

Jul 28, 2022